Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-442-4 | CAS number: 7553-56-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Hypothyroidism in healthy human (sensitive subpopulations):
Boyages et al. 1989 and Li et al 1987 compared the thyroid status in two groups of children (aged 7-15 years). The children resided in two areas of China where drinking water iodide concentrations were either 462.5 μg/L (n=120) or 54 μg/L (N=51) (Boyages et al. 1989; Li et al. 1987). In the high iodine group, there was a 65% prevalence of goitre compared with 15% in the low iodine group. Also, the high iodine group contained 15% of subjects that had a grade 2 goitre, compared with 0% having a grade 2 goitre in the low iodine group. As stated above, although the subjects were all euthyroid with normal values for serum thyroid hormones and TSH concentrations, TSH concentrations were significantly higher (33%) in the high iodine group. These key epidemiological studies are used for endpoint conclusion and dose descriptor from which the chronic NOAEL in humans has been set at 0.01 mg/kg bw/day for the most sensitive sub populations (based on subclinical hypothyroidism in healthy human children). The same data has been used bythe ATSDR and WHO as the basis for setting a mimimum risk level (ATSDR) and a Tolerable Daily Intake (WHO) of 0.01 mg/kg bw/day which are values for acceptable oral chronic exposure to iodine.
In support of developing hypothyroidism in sensitive populations (children), another case report describes a 72 year old female who developed clinical and laboratory evidence of hyperthyroidism while ingesting sea-kelp (Vitalia) tablets. Six months after stopping the tablets, the symptoms and laboratory evidence of hyperthyroidism had disappeared. No evidence of pre-existing thyroid disease was found.
Allergic contact dermatitis:
A number of human case reports of possible allergic contact dermatitis of iodine (PVP-solution) and iodine are reported. Iodine (PVP-solution) was evaluated in a human study.
A report by Oiso (2006) documents a case study whereby a patient treated for a necrotic ulcer of the left ankle was administered an ointment containing 0.9% iodine. The patient had no history of dermatitis herpetiformis. Whilst treating the ulcer, erythema developed 6 months later. Patch testing displayed a positive reaction to the ointment on D2 (+), D3 (+) and D4 (+). Further patch testing was done with the ingredients which was positive on D2 (+++), D3 (+++) and D6 (+) which identified that the iodine component in the ointment was causing the positive reactions. In control patch tests using the ointment, all 6 tested healthy volunteers displayed negative reactions. The study author considered that absorption of iodine in this case study was over a long period of time under occlusive conditions which is likely to have promoted contact sensitisation. The author further concluded that allergic contact dermatitis from iodine is not uncommon and that as iodine containing ointments are usually applied under occlusive conditions, that dermatologists should be aware of allergic reactivity to iodine in topical ointments.
Lachapelle (2005) reported a study where 500 consecutive patients were patch tested with a 10% povidone-iodine solution that was diluted 10 times in water. Readings were made at 2 and 4 days. 14 out of 500 patients (2.8%) displayed a positive reaction. The 14 patients that tested positive were given a repeated open application test with a PVP-I solution were 2 out of 14 patients were regarded as positive. From the repeat test, it was concluded that 2 out of the 500 patients showed true allergic contact dermatitis from PVP-I (0.4%). The study concluded that substances that share both irritant and allergic properties (e.g. PVP-I) should be investigated more thoroughly to rule out false positive patch test results.
Overall, human case studies on the allergic contact dermatitis of iodine are available but with equicocal results.
Additional information
The thyroid gland is the main storage organ for iodine. It is also the target of iodine toxicity. Exposure to excess iodine can lead to hypothyroidism (with or without goitre – enlargement of the thyroid), hyperthyroidism, and changes in the incidence and types of thyroid malignancies (WHO, 2020).
The adverse effects associated with high levels of iodine intake are linked to disruption of thyroid hormone metabolism and the thyroid–pituitary axis, and the compensatory mechanisms that protect this metabolism from low or high levels of iodine intake. Previous exposures to iodine and the complex effects of pre-existing thyroid conditions also influence the effects of subsequent exposure. Members of the general population who are vulnerable to iodine toxicity include pregnant and lactating women, and neonates (WHO, 2020).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.